EX-99.2
Eliem Therapeutics, Inc. completed the acquisition of Tenet Medicines, Inc. on June 27, 2024, integrating Tenet's business, including the TNT119 anti-CD19 antibody program, into Eliem. The combined entity will focus on advancing TNT119 for autoimmune diseases like systemic lupus erythematosus (SLE), immune thrombocytopenia (ITP), and membranous nephropathy (MN). Eliem plans to initiate two Phase 2 clinical trials for TNT119 in SLE and ITP in the second half of 2024, pending FDA clearance, and aims to finalize a high-concentration subcutaneous formulation for TNT119 by the end of 2024.
APR 13·Simply Wall Street→
Climb Bio, Inc. (CLYM) Leadership & Management Team Analysis
This article provides an analysis of Climb Bio, Inc.'s (CLYM) leadership and management team. It details compensation for CEO Aoife Brennan, management and board tenure, and lists recent company updates including executive changes, regulatory designations, and financial activities. The report also compares CEO compensation to market averages and outlines the company's financial data as of December 2025.
OCT 17·GlobeNewswire▲
Climb Bio to Present Data at American Society of Nephrology ( ASN ) Kidney Week 2025
Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy ...
